Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PQR309 in Relapsed or Refractory Lymphoma
NCT03127020Phase 2Completed
- Sponsor
- PIQUR Therapeutics AG
- Start
- Jun 2016
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bimiralisib in lymphoma and non-Hodgkin lymphoma (NHL), sponsored by PIQUR Therapeutics AG. Primary endpoint: Change of Tumor Response Criteria at 48 months. Started Jun 2016; status: completed.
02
Drugs
bimiralisib
03
Conditions
lymphomanon-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03127020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03127020.